Halberd Corporation, in collaboration with Athena Telemedicine Partners, reports positive clinical results for its patent-pending LDX compound in treating...

Syncromune’s Phase 1 clinical trial of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) showed an...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional marketing authorization for mirdametinib, a...

BriaCell Therapeutics Corp. announced positive Phase 2 clinical trial data for its Bria-IMT™ immunotherapy in metastatic breast cancer, demonstrating...

In this conversation, Thad Wolfram, Chief Strategy Officer of EmVenio Research and PCM Trials, shares his insights on the...

Iovance Biotherapeutics announced five-year follow-up data from the Phase 2 C-144-01 trial of its tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi...

Merus N.V. announced interim phase 2 trial data for petosemtamab combined with pembrolizumab in treating head and neck squamous...

ImCheck Therapeutics announced positive interim results from its Phase I/II EVICTION study of ICT01, a novel γ9δ2 T-cell activator,...

Adagene Inc. released updated Phase 1b/2 clinical trial data for ADG126, a novel anti-CTLA-4 antibody, combined with pembrolizumab in...